---
title: "HILE: The transaction price for the major asset purchase has been adjusted to 536 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257327064.md"
description: "HILE announced that it has signed a supplementary agreement with Meilun Management Co., Ltd. to adjust the transaction price for the major asset purchase to 536 million yuan. According to the assessment, the equity value of Ruisheng Bio has been revised down from 1.7 billion yuan to 974 million yuan, and the transaction price has been adjusted from 935 million yuan to 536 million yuan, with Meilun Company returning the difference of 399 million yuan. This adjustment does not affect HILE's holding of 55% equity in Ruisheng Bio and reduces investment risk. The adjusted commitments for non-net profit for 2025 and 2026 are 50 million yuan and 58 million yuan, respectively"
datetime: "2025-09-15T09:13:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257327064.md)
  - [en](https://longbridge.com/en/news/257327064.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257327064.md)
generator: "portal-rs"
---

# HILE: The transaction price for the major asset purchase has been adjusted to 536 million yuan

HILE announced that the company has signed a supplementary agreement with Meilun Management Co., Ltd. to adjust the transaction price for a major asset purchase. According to the assessment by Beijing Zhuoxin Dahua Asset Appraisal Co., Ltd., the total equity value of Ruisheng Bio's shareholders is 974 million yuan, down from the original 1.7 billion yuan. Therefore, the transaction price has been adjusted from 935 million yuan to 536 million yuan, and Meilun will return the price difference of 399 million yuan. This adjustment does not affect the company's holding of 55% equity in Ruisheng Bio and helps to reduce investment risks and the risk of failing to meet performance commitments. The adjusted commitments for non-recurring net profit for 2025 and 2026 are 50 million yuan and 58 million yuan, respectively

### Related Stocks

- [603718.CN](https://longbridge.com/en/quote/603718.CN.md)

## Related News & Research

- [FDA Approves Tablet Form of Zanubrutinib for All Approved Indications](https://longbridge.com/en/news/298434766.md)
- [Ekadharma says Fujian Youjia acquisition price not yet set, to be negotiated based on independent valuation](https://longbridge.com/en/news/298546281.md)
- [Matica Biotechnology and Bondwell Technologies Collaborate to Advance Texas Biotech Innovation](https://longbridge.com/en/news/298444718.md)
- [BYD’s new Defender-like SUV breaks cover for the first time](https://longbridge.com/en/news/298360491.md)
- [Saudi-led coalition in Yemen says 73 people injured in Houthi attacks on the kingdom](https://longbridge.com/en/news/298257269.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**